Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001362692 | SCV001558722 | uncertain significance | Mucopolysaccharidosis, MPS-IV-A | 2021-08-26 | criteria provided, single submitter | clinical testing | This sequence change replaces valine with isoleucine at codon 330 of the GALNS protein (p.Val330Ile). The valine residue is weakly conserved and there is a small physicochemical difference between valine and isoleucine. This variant is present in population databases (rs767856715, ExAC 0.002%). This variant has not been reported in the literature in individuals affected with GALNS-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The isoleucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |